At 10.8% CAGR, North America Prefilled Syringe Market is Projected to be Worth US$ 6,783.62 Million by 2030, Says Business Market Insights

According to Business Market Insights' research, the North America prefilled syringe market was valued at US$ 2,992.69 million in 2022 and is expected to reach US$ 6,783.62 million by 2030, registering a CAGR of 10.8% from 2022 to 2030. Ongoing innovation in prefilled syringes and growing adoption of self-injecting parenteral devices are among the critical factors attributed to the North America prefilled syringe market expansion.

Over a period of time, various aspects of the healthcare industry have been developed to simplify the working process of healthcare professionals and enhance the quality of care by ensuring the safety of patients and healthcare providers. The prefilled syringes have undergone several innovation updates and developments to provide comfort and safety along with a reduction in biomedical waste. Some of the innovations made by manufacturers in prefilled syringes are mentioned below:

•          West Pharmaceutical Services provides line extensions that include insert needle syringes and more needle sizes with product volume options. In the past three to five years, there have been more approvals in the larger 2.5-ml format. The larger volume reduces the amount of syringes needed per dose and enhances efficiency and comfort. There is a growing trend of finer needles too; smaller, thinner needles mean less pain.

•          In collaboration with Gerresheimer and Stevanto Group, Stevanato manufactures its ITC twist-off closure system for Gerresheimer's Gx RTF luer lock syringes. The integrated seal cap is composed of an elastomeric component, which is available in various formulations, and a rigid, translucent polymer cap. Its advantages include greater stability and shelf-life protection versus traditional luer cone systems.

•          Prefilled syringes provide sustainability benefits by reducing multi-dose vials and related production and handling, along with product waste associated with leftover products. There is a lot of room for improvement as the current systems create a lot of waste, owing to which attempts are being made to reduce scrap rates and reuse the tubs that hold nested containers through the fill-finish process.

•          Suppliers are looking for designs to prevent needlestick injuries, protect product quality by minimizing particulates, and eliminate product interaction with tungsten or silicone residues. Gerresheimer Biological Solutions provides metal-free syringes manufactured from tungsten-sensitive products. With this patented technology, the pin meant for conical shaping is made of a ceramic rather than tungsten or other metal.

•          Silicone oil is commonly used to enhance syringe performance, but it can cause aggregation and particulate issues for sensitive biologicals. The ophthalmologists and regulatory bodies are urging them to move away from siliconized formats. Some patients experience reactions to silicone, and over time, with repeated injections, the material can become accumulated. One silicone-free option is paired with ImproJect plungers from W.L. Gore & Associates and SCHOTT BioPure silicone-free syringes from SCHOTT. This system opens the door for many sensitive products to enter the prefilled syringe format. Thorough attention to syringe geometry and dimensions of the syriQ BioPure syringes helps ensure a constant gliding force and injection duration over the shelf-life of the product and upholds container closure integrity without the use of silicone. Minimal cannula adhesive and ultra-low tungsten residuals reduce the extractible profile and the potential for container and drug interactions.

•          To prevent potentially hazardous needlesticks and comply with regulations in various parts of the world, some syringes, such as Gerresheimer’s InnoSafe, incorporate a pre-applied, passive safety device. With this pre-installed device, there is no need for post-filling assembly equipment or for healthcare professionals to install a guard prior to an injection. The advantages include improved compatibility with auto-injectors and a completely hidden needle that provides patients with needle-phobia a better experience. The design also prevents accidental reuse and runs on existing fill/finish lines without any additional equipment or process steps.

•          COVID-19 has increased the development of prefilled syringes, particularly with regard to low-temperature storage. As of now, all COVID-19 vaccines are available in vials, but in the next two to four years, it is expected to be available in novel type of syringe that handles −80ºC.

Therefore, increasing innovations in the prefilled syringes are expected to promote the growth of the prefilled syringes market in the near future.

On the contrary, increasing product recalls hampers the growth of North America prefilled syringe market.

Based on type, the North America prefilled syringe market is bifurcated into disposable prefilled syringes and reusable prefilled syringes. The disposable prefilled syringes segment held 72.9% share of the North America prefilled syringe market in 2022, amassing US$ 2,181.06 million. It is projected to garner US$ 5,052.11 million by 2030 to expand at 11.1% CAGR during 2022–2030.

Based on material, the North America prefilled syringe market is bifurcated into glass prefilled syringes and plastic prefilled syringes. The glass prefilled syringes segment held 58.9% share of the North America prefilled syringe market in 2022, amassing US$ 1,763.74 million. It is projected to garner US$ 3,924.26 million by 2030 to expand at 10.5% CAGR during 2022–2030.

Based on designs, the North America prefilled syringe market is bifurcated into single chamber and multi chamber. The single chamber segment held 67.3% share of the North America prefilled syringe market in 2022, amassing US$ 2,014.09 million. It is projected to garner US$ 4,214.96 million by 2030 to expand at 9.7% CAGR during 2022–2030.

In terms of application, the North America prefilled syringe market is segmented into cancer, diabetes, autoimmune disease, infectious diseases, and others. The others segment held 30.2% share of the North America prefilled syringe market in 2022, amassing US$ 902.36 million. It is projected to garner US$ 1,961.27 million by 2030 to expand at 10.2% CAGR during 2022–2030.

By distribution channel, the North America prefilled syringe market is segmented into hospital pharmacy, retail pharmacy, and online channel. The hospital pharmacy segment held 55.8% share of North America prefilled syringe market in 2022, amassing US$ 1,670.26 million. It is projected to garner US$ 3,917.92 million by 2030 to expand at 11.2% CAGR during 2022–2030.

Based on country, the North America prefilled syringe market is categorized into the US, Canada, and Mexico. The US held 80.5% share of North America prefilled syringe market in 2022, amassing US$ 2,409.27 million. It is projected to garner US$ 5,509.40 million by 2030 to expand at 10.9% CAGR during 2022–2030.

Key players operating in the North America prefilled syringe market are B Braun SE, Shandong Weigao Group Medical Polymer Co Ltd, Gerresheimer AG, Schott AG, Nipro Corp, Becton Dickinson and Co, Baxter International Inc, Terumo Corp, and Ypsomed Holding AG, among others.

• In January 2020, Gerresheimer expanded its range of pre-fillable polymer syringes. The company launched the Gx RTF ClearJect polymer needle syringe, 2.25 ml.
• In May 2023, BD increased customer access to an all-in-one prefilled flush syringe with an integrated disinfection unit meant to reinforce infection prevention principles and streamline nurse workflow. The BD PosiFlush SafeScrub is a prefilled saline flush syringe with an active disinfection unit incorporated straight into the tip cap that has been shown in vitro to drastically minimise bacteria growth associated with CRBSIs.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com